AI assistant
Niagen Bioscience, Inc. — Director's Dealing 2008
Jun 26, 2008
32418_dirs_2008-06-25_7473490b-17cb-4022-a499-3de5dc3d586f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ChromaDex Corp. (CDYE(4))
CIK: 0001386570
Period of Report: 2008-06-25
Reporting Person: Jaksch Frank L Jr (Director, President and CEO, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6225155 | Direct |
| Common Stock | 1429000 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.5 | 2016-12-01 | Common Stock (300000) | Direct | |
| Stock Option (Right to Buy) | $1.5 | 2018-04-21 | Common Stock (700000) | Direct | |
| Stock Option (Right to Buy) | $1.5 | 2018-04-21 | Common Stock (150000) | Direct |
Footnotes
F1: 60,000 options are exercisable at any time, at the holder's discretion and 60,000 additional options become exercisable annually on December 1.
F2: 175,000 options become exercisable on April 21, 2009 and 10,937 options become exercisable monthly thereafter, except that 10,938 options become exercisable every other month.
F3: 37,500 options become exercisable on April 21, 2009 and 2,343 options become exercisable monthly thereafter, except that 2,344 options become exercisable every other month and 2,345 options become exercisable every fourth month.